Trastuzumab-based combinations in metastatic breast cancer

How to make a choice

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Trastuzumab, a humanized monoclonal anti-human epidermal growth factor receptor-2 (HER2) antibody that has proven efficacy as monotherapy in HER2-overexpressing breast cancer, has a favorable toxicity profile characterized by infrequent infusion reactions and a slightly increased incidence of cardiac dysfunction. Regimens that combine trastuzumab with a cytotoxic agent can increase the overall response rate and prolong survival in patients with metastatic breast cancer. Trastuzumab has been investigated in combination with anthracyclines, taxanes, platinum salts, vinorelbine, gemcitabine, capecitabine, and combinations of these agents. Combining trastuzumab with these agents enhances the toxicity of treatment and can especially enhance the risk of cardiotoxicity. This article summarizes data on trastuzumab-based combinations with particular attention to the risk benefit ratio of these therapies. HER2 testing by immunohistochemistry or fluorescence in situ hybridization is discussed in the context of determining the optimal course of treatment for patients.

Original languageEnglish
Pages (from-to)28-38
Number of pages11
JournalClinical Breast Cancer
Volume4
Issue number1
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Breast Neoplasms
gemcitabine
Taxoids
Anthracyclines
Cytotoxins
Platinum
Fluorescence In Situ Hybridization
Therapeutics
Survival Rate
Salts
Immunohistochemistry
Odds Ratio
Trastuzumab
Antibodies
Incidence
human ERBB2 protein

Keywords

  • Combination chemotherapy
  • Docetaxel
  • Paclitaxel
  • Platinum-based chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research

Cite this

Trastuzumab-based combinations in metastatic breast cancer : How to make a choice. / Jahanzeb, Mohammad.

In: Clinical Breast Cancer, Vol. 4, No. 1, 01.01.2003, p. 28-38.

Research output: Contribution to journalArticle

@article{ca0c8ce1e0174155bba269cf38bd52bb,
title = "Trastuzumab-based combinations in metastatic breast cancer: How to make a choice",
abstract = "Trastuzumab, a humanized monoclonal anti-human epidermal growth factor receptor-2 (HER2) antibody that has proven efficacy as monotherapy in HER2-overexpressing breast cancer, has a favorable toxicity profile characterized by infrequent infusion reactions and a slightly increased incidence of cardiac dysfunction. Regimens that combine trastuzumab with a cytotoxic agent can increase the overall response rate and prolong survival in patients with metastatic breast cancer. Trastuzumab has been investigated in combination with anthracyclines, taxanes, platinum salts, vinorelbine, gemcitabine, capecitabine, and combinations of these agents. Combining trastuzumab with these agents enhances the toxicity of treatment and can especially enhance the risk of cardiotoxicity. This article summarizes data on trastuzumab-based combinations with particular attention to the risk benefit ratio of these therapies. HER2 testing by immunohistochemistry or fluorescence in situ hybridization is discussed in the context of determining the optimal course of treatment for patients.",
keywords = "Combination chemotherapy, Docetaxel, Paclitaxel, Platinum-based chemotherapy, Vinorelbine",
author = "Mohammad Jahanzeb",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "28--38",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Trastuzumab-based combinations in metastatic breast cancer

T2 - How to make a choice

AU - Jahanzeb, Mohammad

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Trastuzumab, a humanized monoclonal anti-human epidermal growth factor receptor-2 (HER2) antibody that has proven efficacy as monotherapy in HER2-overexpressing breast cancer, has a favorable toxicity profile characterized by infrequent infusion reactions and a slightly increased incidence of cardiac dysfunction. Regimens that combine trastuzumab with a cytotoxic agent can increase the overall response rate and prolong survival in patients with metastatic breast cancer. Trastuzumab has been investigated in combination with anthracyclines, taxanes, platinum salts, vinorelbine, gemcitabine, capecitabine, and combinations of these agents. Combining trastuzumab with these agents enhances the toxicity of treatment and can especially enhance the risk of cardiotoxicity. This article summarizes data on trastuzumab-based combinations with particular attention to the risk benefit ratio of these therapies. HER2 testing by immunohistochemistry or fluorescence in situ hybridization is discussed in the context of determining the optimal course of treatment for patients.

AB - Trastuzumab, a humanized monoclonal anti-human epidermal growth factor receptor-2 (HER2) antibody that has proven efficacy as monotherapy in HER2-overexpressing breast cancer, has a favorable toxicity profile characterized by infrequent infusion reactions and a slightly increased incidence of cardiac dysfunction. Regimens that combine trastuzumab with a cytotoxic agent can increase the overall response rate and prolong survival in patients with metastatic breast cancer. Trastuzumab has been investigated in combination with anthracyclines, taxanes, platinum salts, vinorelbine, gemcitabine, capecitabine, and combinations of these agents. Combining trastuzumab with these agents enhances the toxicity of treatment and can especially enhance the risk of cardiotoxicity. This article summarizes data on trastuzumab-based combinations with particular attention to the risk benefit ratio of these therapies. HER2 testing by immunohistochemistry or fluorescence in situ hybridization is discussed in the context of determining the optimal course of treatment for patients.

KW - Combination chemotherapy

KW - Docetaxel

KW - Paclitaxel

KW - Platinum-based chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0038783098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038783098&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 28

EP - 38

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -